CRISPR RNA Editing Turns “Invisible” Prostate Tumors into Targets for Immunotherapy

/in , , /by

Prostate cancer usually responds poorly to immunotherapy because the tumor hides from the immune system, earning the label of an “immune‑cold” cancer. A new RNA‑targeted CRISPR technology developed at Duke University School of Medicine and collaborating institutions re‑exposes these tumors to immune attack in mice by restoring a key protein complex on cancer cells that […]

Read more

CRISPR’s New Kill‑Switch: Targeting Cancer Cells by Their RNA Signature

/in , /by

A new CRISPR system recently published in Nature could change how we think about selectively eliminating cancer cells without touching healthy tissue. Instead of using the classic Cas9 to edit DNA, researchers have repurposed Cas12a2, an enzyme that first binds to a specific RNA sequence and then unleashes a wave of DNA destruction across the […]

Read more

CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future

/in , /by

A new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters […]

Read more

A New Weak Spot in Prostate Cancer: Disarming the Androgen Signal by Targeting PTGES3

/in , /by

A new study shows, published on Nature, that a little-known protein called PTGES3 helps prostate cancer cells keep using male hormone signals to grow, even when treatments are trying to shut those signals down. Blocking this helper protein cut off the cancer’s fuel supply in lab tests and slowed tumors in mice, pointing to a […]

Read more